PALO ALTO, Calif., Dec. 2, 2019 /PRNewswire/ -- Kodiak Sciences
Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company
specializing in novel therapeutics to treat chronic,
high-prevalence retinal diseases, today announced that management
will present at the Evercore ISI HealthCONx Conference in
Boston, MA on Tuesday, December 3 at 1:15 p.m. Eastern Time.
A live webcast of the presentation will be available on the
"Investors & Media" section of Kodiak's website at
http://ir.kodiak.com/ and will remain available for replay for
a limited time following the event.
About Kodiak Sciences Inc.
Kodiak™ is a clinical stage biopharmaceutical company
specializing in novel therapeutics to treat chronic,
high-prevalence retinal diseases. We are focused on bringing new
science to the design and manufacture of next generation retinal
medicines to prevent and treat the leading causes of blindness
globally. Our ABC Platform™ merges the fields of antibody-based and
chemistry-based therapies and is at the core of Kodiak's discovery
engine. Kodiak's lead product candidate, KSI-301, is a novel
anti-VEGF antibody biopolymer conjugate being developed for the
treatment of retinal vascular diseases including age-related
macular degeneration and diabetic eye diseases. Kodiak has
leveraged its ABC Platform to build a pipeline of product
candidates in various stages of development including KSI-501, our
bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of
neovascular retinal diseases with an inflammatory component, and we
are expanding our early research pipeline to include ABC Platform
based triplet inhibitors for multifactorial retinal diseases such
as dry AMD and the neurodegenerative aspects of glaucoma. Kodiak is
based in Palo Alto, CA. For more
information, visit www.kodiak.com.
"Kodiak," "ABC Platform" and the Kodiak logo are registered
trademarks or trademarks of Kodiak Sciences Inc. in various
jurisdictions.
View original
content:http://www.prnewswire.com/news-releases/kodiak-sciences-to-present-at-the-evercore-isi-healthconx-conference-300967165.html
SOURCE Kodiak Sciences Inc.